This is a phase II, randomized, double-blind, placebo-controlled study to evaluate the weight loss effects of daily subcutaneous administration of A-100 in obese subjects. Participants will be taught to self-inject starting at the part B visit during the screening period. After screening, eligible subjects will be randomized to 2ml A-100, 4ml A-100; 2ml placebo, in a 2:2:2:1 ratio. This study is expected to last approximately 12 months, with an 8 month study duration for each participant. Participants will be monitored with physical exams, dietary intervention and behavior modification, body composition, and periodic laboratory analysis.
Showing the most recent 10 out of 412 publications